Proficiency Testing for Meropenem and Piperacillin Therapeutic Drug Monitoring: Preliminary Results From the Belgian Society on Infectiology and Clinical Microbiology Pharmacokinetic-Pharmacodynamic Working Group
Carlier, M.; Athanasopoulos, A.; Borrey, D.et al.
2018 • In Therapeutic Drug Monitoring, 40 (1), p. 156-158
Anti-Bacterial Agents; Drug Monitoring; Humans; Laboratory Proficiency Testing; Piperacillin; Thienamycins
Disciplines :
General & internal medicine
Author, co-author :
Carlier, M.; Department of Laboratory Medicine, Ghent University Hospital, Ghent, Belgium
Athanasopoulos, A.; Department of Clinical Chemistry, University Hospital of Charleroi, Charleroi, Belgium
Borrey, D.; Department of Clinical Chemistry, AZ Sint Jan Brugge, Bruges, Belgium
Colin, P.; Unit of Medical Biochemistry and Clinical Analysis, Department of Bioanalysis, Faculty of Pharmaceutical Sciences, Ghent University, Ghent, Belgium
Cotton, F.; Department of Clinical Chemistry, Erasme Hospital, Brussels, Belgium
Denooz, Raphaël ; Université de Liège - ULiège > Département de pharmacie > Département de pharmacie
Neels, H.; Department of Clinical Chemistry, Ziekenhuisnetwerk Antwerpen, Antwerp, Belgium
Spriet, I.; Clinical Pharmacology and Pharmacotherapy, University Hospital Leuven, Leuven, Belgium
Ghys, T.; Department of Clinical Chemistry, AZ Sint Lucas Gent, Ghent, Belgium
Verstraete, A. G.; Department of Laboratory Medicine, Ghent University Hospital, Ghent, Belgium, Department of Clinical Chemistry, Microbiology and Immunology, Ghent University, Ghent, Belgium
Stove, V.; Department of Laboratory Medicine, Ghent University Hospital, Ghent, Belgium, Department of Clinical Chemistry, Microbiology and Immunology, Ghent University, Ghent, Belgium
Language :
English
Title :
Proficiency Testing for Meropenem and Piperacillin Therapeutic Drug Monitoring: Preliminary Results From the Belgian Society on Infectiology and Clinical Microbiology Pharmacokinetic-Pharmacodynamic Working Group
Publication date :
2018
Journal title :
Therapeutic Drug Monitoring
ISSN :
0163-4356
eISSN :
1536-3694
Publisher :
Lippincott Williams & Wilkins, United States - Maryland
Vincent JL, Rello J, Marshall J, et al. International study of the prevalence and outcomes of infection in intensive care units. J Am Med Assoc. 2009; 302:2323-2329.
Roberts J, Paul S, Akova M, et al. DALI: defining antibiotic levels in intensive care unit patients: are current beta-lactam antibiotic doses sufficient for critically ill patients. Clin Infect Dis. 2014; 58:1072-1083.
Craig WA Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis. 1998; 26:1-10.
Roberts DM, Roberts JA, Roberts MS, et al. Variability of antibiotic concentrations in critically ill patients receiving continuous renal replacement therapy: a multicentre pharmacokinetic study. Crit Care Med. 2012; 40: 1523-1528.
Udy AA, Varghese JM, Altukroni M, et al. Subtherapeutic initial beta-lactam concentrations in select critically ill patients: association between augmented renal clearance and low trough drug concentrations. Chest. 2012; 142: 30-39.
Carlier M, Carrette S, Roberts J, et al. Meropenem and piperacillin/tazobactam prescribing in critically ill patients: does augmented renal clearance affect pharmacokinetic/pharmacodynamic target attainment when extended infusions are used? Crit Care. 2013; 17:R84.
Carlier M, Carrette S, Stove V, et al. Does consistent piperacillin dosing result in consistent therapeutic concentrations in critically ill patients? a longitudinal study over an entire antibiotic course. Int J Antimicrob Agents. 2014; 43:470-473.
De Waele JJ, Carrette S, Carlier M, et al. Therapeutic drug monitoring-based dose optimisation of piperacillin and meropenem: a randomised controlled trial. Intens Care Med. 2014; 40:380-387.
Fournier A, Eggimann P, Pagani JL, et al. Impact of the introduction of real-time therapeutic drug monitoring on empirical doses of carbapenems in critically ill burn patients. Burns. 2015; 41:956-968.
Hayashi Y, Lipman J, Udy AA, et al. β-Lactam therapeutic drug monitoring in the critically ill: optimising drug exposure in patients with fluctuating renal function and hypoalbuminaemia. Int J Antimicrob Agents. 2013; 41: 162-166.
Lonsdale DO, Udy AA, Roberts JA, et al. Antibacterial therapeutic drug monitoring in cerebrospinal fluid: difficulty in achieving adequate drug concentrations. J Neurosurg. 2013; 118:297-301.
Bretonniere C, Leone M, Milesi C, et al. Strategies to reduce curative antibiotic therapy in intensive care units (adult and paediatric). Intensive Care Med. 2015; 41: 1181-1196.
Carlier M, Stove V, Wallis SC, et al. Assays for therapeutic drug monitoring of β-lactam antibiotics: a structured review. Int J Antimicrob Agents. 2015; 46:367-375.
Guidance for Industry Bioanalytical Method Validation. Silver Spring, MD. U.S. Department of Health and Human Services Food and Drug Administration; 2001.
Guideline on Bioanalytical Method Validation. United Kingdom. European Medicine Agency; 2011.
